Article
Oncology
Ying Cheng, Yong He, Wei Li, He-long Zhang, Qing Zhou, Buhai Wang, Chunling Liu, Andrew Walding, Matilde Saggese, Xiangning Huang, Minhao Fan, Jia Wang, Suresh S. Ramalingam
Summary: The FLAURA China study evaluated the efficacy of first-line osimertinib in Chinese patients with EGFRm advanced NSCLC, showing significant improvements in PFS and OS compared to comparator EGFR TKIs. Safety data were consistent with the known safety profile of osimertinib.
Article
Medicine, General & Internal
D. Planchard, P. A. Janne, Y. Cheng, J. C. -H. Yang, N. Yanagitani, S-W Kim, S. Sugawara, Y. Yu, Y. Fan, S. L. Geater, K. Laktionov, C. K. Lee, N. Valdiviezo, S. Ahmed, J-M Maurel, I Andrasina, J. Goldman, D. Ghiorghiu, Y. Rukazenkov, A. Todd, K. Kobayashi
Summary: The study indicates that first-line treatment with osimertinib-chemotherapy significantly prolongs progression-free survival compared to osimertinib monotherapy in patients with EGFR-mutated advanced NSCLC.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
K. Tamura, T. Yoshida, K. Masuda, Y. Matsumoto, Y. Shinno, Y. Okuma, Y. Goto, H. Horinouchi, N. Yamamoto, Y. Ohe
Summary: This retrospective study investigated the activity of EGFR-TKIs in untreated EGFR-mutated NSCLC patients with leptomeningeal metastases (LM). The results showed that osimertinib had better outcomes in LM compared to first-generation TKIs, especially in patients with exon 19 deletion.
Article
Multidisciplinary Sciences
Motohiro Tamiya, Akihiro Tamiya, Norio Okamoto, Yoshihiko Taniguchi, Kazumi Nishino, Shinji Atagi, Tomonori Hirashima, Fumio Imamura, Toru Kumagai, Hidekazu Suzuki
Summary: In this study, it was found that treating T790M-positive NSCLC patients with afatinib followed by osimertinib may lead to better outcomes. The T790M ratio was significantly correlated with osimertinib response, and there was no significant difference in T790M ratio between the Afa group and 1st-G group.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Yuhong Liu, Xiaoyong Dai, Shengwei Jiang, Mulan Qahar, Chunyan Feng, Dongdong Guo, Lijun Wang, Shaohua Ma, Laiqiang Huang
Summary: The combination of rapamycin and gefitinib has been shown to enhance the therapeutic efficacy in overcoming gefitinib resistance in NSCLC. Additionally, targeted delivery of the drugs using an aptamer-nanoparticle carrier system further enhances the therapeutic efficacy of gefitinib.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Kenichi Koyama, Satoru Miura, Satoshi Watanabe, Satoshi Shoji, Jun Koshio, Yoshiki Hayashi, Daisuke Ishikawa, Ko Sato, Takao Miyabayashi, Masaaki Okajima, Takeshi Ota, Tomohiro Tanaka, Naoya Matsumoto, Hideyuki Kuriyama, Tetsuya Abe, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Hiroshi Tanaka, Toshiaki Kikuchi
Summary: Rebiopsy is crucial in selecting optimal treatments for NSCLC patients with acquired resistance mutations, with a high implementation rate of 90.8% observed in Japanese clinical practice. Obtaining histological or cytological tissue samples during rebiopsy may contribute to improving the detection rate of the T790M mutation.
SCIENTIFIC REPORTS
(2022)
Article
Critical Care Medicine
Shun Lu, Jianying Zhou, Hong Jian, Lin Wu, Ying Cheng, Yun Fan, Jian Fang, Gongyan Chen, Zhihong Zhang, Dongqing Lv, Liyan Jiang, Rong Wu, Xiangming Jin, Xiaodong Zhang, Junhong Zhang, Conghua Xie, Gengyun Sun, Dongning Huang, Jiuwei Cui, Renhua Guo, Zhigang Han, Zhendong Chen, Jin Liang, Wu Zhuang, Xingsheng Hu, Aimin Zang, Yi Zhang, Shundong Cang, Yuanbo Lan, Xi Chen, Laiyu Liu, Xingya Li, Jun Chen, Rui Ma, Yanzhen Guo, Ping Sun, Panwen Tian, Yueyin Pan, Zhe Liu, Peiguo Cao, Lieming Ding, Yang Wang, Xiaobin Yuan, Pengxiang Wu
Summary: This phase 3 trial compared the efficacy and safety of befotertinib with icotinib as a first-line treatment for patients with EGFR mutation-positive NSCLC. The study found that befotertinib demonstrated superior efficacy in terms of progression-free survival compared to icotinib, although it was associated with more frequent adverse events.
LANCET RESPIRATORY MEDICINE
(2023)
Article
Oncology
Chunsheng Wang, Kewei Zhao, Shanliang Hu, Wei Dong, Yan Gong, Minghuan Li, Conghua Xie
Summary: By studying the outcomes of gefitinib and erlotinib in patients with uncommon EGFR mutations in non-small cell lung cancer (NSCLC), it was found that patients with compound mutations had better treatment response, with those containing exon 19 deletion or L858R mutations showing the most significant benefits in response and survival. Additionally, the gefitinib group showed superior treatment efficacy and PFS benefit compared to the erlotinib group.
Article
Biology
Leilei Zhu, Shanshan Gao, Xianya Zhao, Ying Wang
Summary: This study identifies key genes related to EGFR-TKI resistance in NSCLC through bioinformatics analysis and predicts potential drugs for treating EGFR-TKI-resistant NSCLC.
LIFE SCIENCE ALLIANCE
(2023)
Review
Medicine, General & Internal
Dailong Li, Ling Yao, Lu Xu, Wanqiang Li, Yuan Che
Summary: Icotinib is found to be more effective and safer than gefitinib or erlotinib in treating advanced EGFR mutation-positive NSCLC according to a systematic evaluation.
Article
Medicine, General & Internal
Masahiro Tsuboi, Roy S. Herbst, Thomas John, Terufumi Kato, Margarita Majem, Christian Grohe, Jie Wang, Jonathan W. Goldman, Shun Lu, Wu-Chou Su, Filippo de Marinis, Frances A. Shepherd, Ki Hyeong Lee, Nhieu Thi Le, Arunee Dechaphunkul, Dariusz Kowalski, Lynne Poole, Ana Bolanos, Yuri Rukazenkov, Yi-Long Wu
Summary: Among patients with resected, EGFR-mutated, stage IB to IIIA NSCLC, adjuvant osimertinib therapy resulted in significantly longer overall survival compared to placebo in the ADAURA trial. These findings demonstrate that adjuvant osimertinib provides a survival benefit for patients with completely resected, EGFR-mutated, stage IB to IIIA NSCLC.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Multidisciplinary Sciences
Tzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Chin-Chou Wang, Ho-Wen Ko, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Summary: This study compared the efficacy of EGFR-TKI monotherapy and EGFR-TKI plus bevacizumab in real-world non-small cell lung cancer patients with EGFR mutation. The results showed that EGFR-TKI plus bevacizumab significantly improved overall survival and reduced the risk of death compared to EGFR-TKI monotherapy.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Mikkel G. Terp, Kirstine Jacobsen, Miguel Angel Molina, Niki Karachaliou, Hans C. Beck, Jordi Bertran-Alamillo, Ana Gimenez-Capitan, Andres F. Cardona, Rafael Rosell, Henrik J. Ditzel
Summary: Resistance to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC patients is often associated with increased FGFR1 expression and Akt activation, leading to the development of targeted therapy strategies for overcoming resistance. Combination therapy targeting both FGFR and Akt has shown superior growth inhibition of resistant cells in vitro and in vivo, providing a promising rationale for future clinical trials in NSCLC patients.
NPJ PRECISION ONCOLOGY
(2021)
Article
Oncology
Po-Lan Su, Jeng-Shiuan Tsai, Szu-Chun Yang, Yi-Lin Wu, Yau-Lin Tseng, Chao-Chun Chang, Yi-Ting Yen, Chia-Ying Lin, Chien-Chung Lin, Chin-Chou Wang, Meng-Chih Lin, Wu-Chou Su
Summary: Osimertinib-based combination therapy showed better overall survival for NSCLC patients with disease progression after osimertinib treatment, supported by synergism with chemotherapy and a higher proportion of apoptosis cells. These findings suggest the potential benefit of osimertinib-based combination therapy and warrant further validation in randomized controlled studies.
Article
Chemistry, Medicinal
Kenji Mishiro, Ryuichi Nishii, Izumi Sawazaki, Tomoki Sofuku, Takeshi Fuchigami, Hitomi Sudo, Nurmaya Effendi, Akira Makino, Yasushi Kiyono, Kazuhiro Shiba, Junichi Taki, Seigo Kinuya, Kazuma Ogawa
Summary: Researchers attempted to develop nuclear imaging probes for detecting EGFR mutations. They designed and synthesized radioactive or nonradioactive osimertinib derivatives and evaluated their activity. The results showed that these derivatives accumulated significantly higher in tumors with mutations compared to normal tissues, but they also showed high accumulation in the lungs. Therefore, further structural modifications of the probes are needed.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)